Cecilia Pessoa Gingerich

Abbott’s updated MitraClip is a catheter-bases system that provides an alternative to open heart surgery for repairing mitral regurgitation.

An NYU study showed that physicians at small, independent primary care practices report much lower rates of burnout—13.5% compared to the 54.4% national average.

The inverse association between coffee-drinking and all-cause mortality held even for participants with genetic variations affecting caffeine metabolism.

The new formulation allows patients with schizophrenia to begin treatment with just one oral dose of aripiprazole, achieving relevant levels in 4 days.

A study of low-income mothers found that participants who experienced problem-solving sessions reported 11% lower stress compared to controls.

Just 12% of the US population, African-Americans account for nearly 50% of the HIV/AIDS cases in the country.

Plazomicin (Zemdri, Achaogen) is designed to treat certain multi-drug resistant complicated urinary tract infections in adults.

The FRESCA Medical, Inc system is designed to operate with less airflow, alleviating some of the complaints that arise with traditional CPAP systems for patients with obstructive sleep apnea.

Cannabidiol (Epidiolex) is the first drug containing a marijuana-derived substance to receive FDA approval.

Children born early preterm (gestational age 22-33 weeks) scored an average of 0.24 SD higher than children born full term. For girls, this increased to 0.8 SD higher than term born sisters.

Impel NeuroPharma will study the safety and tolerability of dihydroergotamine delivered through the company’s Precision Olfactory Delivery device.

The system’s algorithm predicts glucose levels 30 minutes in advance and adjusts insulin delivery to reduce hypoglycemic events.

The Eversense CGM System sensor is implanted into the patient’s arm and sends glucose data every 5 minutes to a mobile app.

The Qualified Infections Disease Product (QIDP) designation gives ACX-362E access to incentives including Priority Review and eligibility for Fast track status.

An interactive parent-child therapy appears to reduce depression in children 3-6 years old. Interestingly, the therapy also improved symptoms of clinical depression in participating parents.

The buprenorphine and naloxone sublingual film is approved for the treatment of opioid abuse disorder in combination with counseling and psychosocial support.

Patients treated with ocrelizumab had a 6.2% risk of progressing to wheelchair use compared to people taking placebo who had a 9.8% risk.

At 29th of 195 countries, the US in the 9th decile along with countries including the UK, Malta, Lebanon, Singapore, and South Korea.

The catheter is now indicated for use with an aspiration technique for blood clot removal in patients with acute ischemic stroke.

The wearable device, Drug Relief, is a non-narcotic option for treatment and eases withdrawal symptoms within just 30-60 minutes.

The oral treatment was safe and efficacious over the course of a 12-week treatment period.

New drugs are celebrated for the lives they can improve, but it’s a long and arduous journey for those developing them and most treatments don’t make it to FDA approval.

The biologic was previously approved for patients with hemophilia A with factor VIII inhibitors, but additional results indicated efficacy for patient without factor VIII inhibitors as well.

A survey of internal medicine residents found that differing professional needs and perceptions of the field of cardiology were strongly associated with decisions to pursue or avoid cardiology careers.

The supplemental New Drug Application for perampanel (Fycompa) expands the indication to include pediatric patients 2-12 years of age.

Eltrombopag (Promacta) was granted Priority Review designation, indicating a 6-month timeline for review.

The use of diethylstilbestrol during pregnancy was associated with 36% higher odds of ADHD among grandchildren.

The supplemental BLA would expand Coagadex’s prescribing information to include prophylactic and pediatric data.

The study estimated that full achievement of the 2017 hypertension guidelines would prevent 610,000 major cardiovascular events and 334,000 deaths in the US annually.

Taltz (ixekizumab) is the first FDA-approved treatment for moderate to severe plaque psoriasis that includes data on psoriasis in the genital area.